In this webinar, we'll discuss materials and methods to enable the expression of biomolecules on EVs. Data will be shared for using protein scaffolds, such as PTGFRN and BASP-1, that are clinically proven to effectively load therapeutic proteins on the surface or lumen of EVs. Chemical linkers were developed to link nucleic acids or small molecules to the EV membrane while preserving their bioactivity and potency. We will also present case study clinical-stage data and further platform developments.
- Learn why EVs including exosomes are a promising modality to deliver therapeutic payload with an excellent safety profile
- Find out how novel linking and loading technologies can enable the precision engineering of EVs, through case study examples and clinical stage data
- See clinical data for therapeutics that have completed Phase 1 studies within oncology applications, including exoSTING™, exoASO-STAT6™, and exoIL-12™
- Platforms and related clinical assets described here were acquired from Codiak Biosciences and are now available to pharma, biotech, and academic communities